Latest Comments
Advanced Therapy Medicinal Products: Navigating the EU Regulatory Pathway
Advanced therapy medicinal products (ATMPs) — gene therapies, somatic-cell therapies and tissue-engineered products — are among the most complex products to bring to the European[…]
Orphan Drug Designation in the EU: Framework and Reform
Orphan designation is one of the most valuable regulatory assets in Europe — and the rules that govern it are about to change for the[…]
Variations and Lifecycle Management: What Changed for 2026
The EU variations framework has just been through its most significant revision in over a decade — and the rules changed on a different date[…]
eCTD Submissions: Avoiding the Most Common Deficiencies
An eCTD dossier can be scientifically flawless and still fail at the door. Most submission delays are technical, not clinical — and nearly all of[…]
Navigating EOF Marketing Authorizations: What Sponsors Need to Know
Bringing a medicine to the Greek market starts with a marketing authorization — but the route you choose, and how well your dossier is prepared,[…]